Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception.
Most delta-opioid receptors are located on the presynaptic terminals of primary afferent neurons in the spinal cord. However, their presence in different phenotypes of primary afferent neurons and their contribution to the analgesic effect of delta-opioid agonists are not fully known. Resiniferatoxin (RTX) is an ultra-potent transient receptor potential vanilloid type 1 channel (TRPV1) agonist and can selectively remove TRPV1-expressing primary afferent neurons. In this study, we determined the role of delta-opioid receptors expressed on TRPV1 sensory neurons in the antinociceptive effect of the delta-opioid receptor agonists [D-Pen(2),D-Pen(5)]-enkephalin and [D-Ala(2),Glu(4)]-deltorphin. Nociception was measured by testing the mechanical withdrawal threshold in the hindpaw of rats. Changes in the delta-opioid receptors were assessed using immunocytochemistry and the [(3)H]-naltrindole radioligand binding. In RTX-treated rats, the delta-opioid receptor on TRPV1-immunoreactive dorsal root ganglion neurons and afferent terminals in the spinal cord was diminished. RTX treatment also significantly reduced the maximal specific binding sites (31%) of the delta-opioid receptors in the dorsal spinal cord. Interestingly, intrathecal injection of [D-Pen(2),d-Pen(5)]-enkephalin or [D-Ala(2),Glu(4)]-deltorphin produced a large and prolonged increase in the nociceptive threshold in RTX-treated rats. These findings indicate that loss of TRPV1-expressing afferent neurons leads to a substantial reduction in presynaptic delta-opioid receptors in the spinal dorsal horn. However, the effect of delta-opioid agonists on mechano-nociception is paradoxically potentiated in the absence of TRPV1-expressing sensory neurons. This information is important to our understanding of the cellular sites and mechanisms underlying the spinal analgesic effect of delta-opioid agonists.
Chen
Shao-Rui
SR
Department of Anesthesiology and Pain Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, United States. schen@mdanderson.org
Pan
Hui-Lin
HL
D000701:Analgesics, Opioid / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004224:Diterpenes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006930:Hyperalgesia / Q000188:drug therapy*; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D017288:Pain Threshold / Q000187:drug effects*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000819:agonists* / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000378:metabolism*; D013116:Spinal Cord / Q000473:pathology*; D050916:TRPV Cation Channels / Q000819:agonists / Q000378:metabolism*; D014316:Tritium / Q000378:metabolism
D000701:Analgesics, Opioid; D004224:Diterpenes; D009842:Oligopeptides; D017465:Receptors, Opioid, delta; D050916:TRPV Cation Channels; C493922:Trpv1 protein, rat; D014316:Tritium; C060209:deltorphin II, Ala(2)-; D009271:Naltrexone; D020881:Enkephalin, D-Penicillamine (2,5)-; C024353:resiniferatoxin; C055382:naltrindole